Biological treatments for SAPHO syndrome: An update

Inflammation and Allergy - Drug Targets

Volumn 13, Issue 3, 2014, Pages 199-205

  Firinu, Davide ^a   Murgia, Giuseppe ^a   Lorrai, Maria Maddalena ^a   Barca, Maria Pina ^a   Peralta, Maria Monica ^a   Manconi, Paolo Emilio ^a   del Giacco, Stefano R ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Anakinra; Autoinflammatory; Biologicals; Canakinumab; CRMO; Cytokine; Inflammation; Interleukin 1 ; Osteitis; TNF; Ustekinumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 12P40; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB; IMMUNOLOGIC FACTOR; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; CYCLOSPORIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ANTERIOR CHEST WALL SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; DACTYLITIS; HUMAN; IMAGING; INTERVERTEBRAL DISK DEGENERATION; JOINT INJURY; PHYSICAL DISEASE BY ANATOMICAL STRUCTURE; PROPIONIBACTERIUM ACNES; PUSTULOSIS PALMOPLANTARIS; SAPHO SYNDROME; SIGNAL TRANSDUCTION; SKIN DISEASE; SUPPURATIVE HIDRADENITIS; UVEITIS; ACQUIRED HYPEROSTOSIS SYNDROME; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; PATHOPHYSIOLOGY; BIOLOGICAL THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DRUG EFFICACY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PUSTULAR PSORIASIS; SCINTIGRAPHY;

ACQUIRED HYPEROSTOSIS SYNDROME; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904104796     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528113666140520100402     Document Type: Article

References (71)

1. Nguyen, M.T.; Borchers, A.; Selmi, C.; Naguwa, S.M.; Cheema, G.; Gershwin, M.E. The SAPHO syndrome. Semin. Arthritis Rheum., 2012, 42(3), 254-265.
2. Yamamoto, T. Pustulotic arthro-osteitis associated with palmoplantar pustulosis. J. Dermatol., 2013, 40(11), 857-863.
3. Yabe, H.; Ohshima, H.; Takano, Y.; Koyanagi, T.; Usui, H.; Nojiri, K.; Ochi, K.; Kihara, M.; Horiuchi, Y. Mucosal lesions may be a minor complication of SAPHO syndrome: a study of 11 Japanese patients with SAPHO syndrome. Rheumatol Int, 2010, 30(10), 1277-1283.
4. McGonagle, D.; McDermott, M.F. A proposed classification of the immunological diseases. PLoS Med., 2006, 3(8), e297.
5. Braun-Falco, M.; Ruzicka, T. Skin manifestations in autoinflammatory syndromes. J. Dtsch. Dermatol. Ges., 2011, 9(3), 232-246.
6. Stern, S.M.; Ferguson, P.J. Autoinflammatory bone diseases. Rheum. Dis. Clin. North Am., 2013, 39(4), 735-749.
7. Firinu, D.; Barca, M.P.; Lorrai, M.M.; Perra, S.; Cabras, S.; Muggianu, E.; Di Martino, M.L.; Manconi, P.E.; Del Giacco, S.R. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity, 2014, [E-pub ahead of print].
8. Wipff, J.; Adamsbaum, C.; Kahan, A.; Job-Deslandre, C. Chronic recurrent multifocal osteomyelitis. Joint Bone Spine, 2011, 78(6), 555-560.
9. Beretta-Piccoli, B.C.; Sauvain, M.J.; Gal, I.; Schibler, A.; Saurenmann, T.; Kressebuch, H.; Bianchetti, M.G. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. Eur. J. Pediatr., 2000, 159(8), 594-601.
10. Hayem, G.; Bouchaud-Chabot, A.; Benali, K.; Roux, S.; Palazzo, E.; Silbermann-Hoffman, O.; Kahn, M.F.; Meyer, O. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin. Arthritis Rheum., 1999, 29(3), 159-171.
11. Colina, M.; Govoni, M.; Orzincolo, C.; Trotta, F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum., 2009, 61(6), 813-821.
12. Benhamou, C.L.; Chamot, A.M.; Kahn, M.F. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin. Exp. Rheumatol., 1988, 6(2), 109-112.
13. Tlougan, B.E.; Podjasek, J.O.; O'Haver, J.; Cordova, K.B.; Nguyen, X.H.; Tee, R.; Pinckard-Hansen, K.C.; Hansen, R.C. Chronic recurrent multifocal osteomyelitis (CRMO) and synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with associated neutrophilic dermatoses: a report of seven cases and review of the literature. Pediatr. Dermatol., 2009, 26(5), 497-505.
14. Vilar-Alejo, J.; Dehesa, L.; de la Rosa-del Rey, P.; Novoa-Medina, J.; Valeron Almazan, P.; Santana Medina, N.; Bastida, J. SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept. Acta Derm. Venereol., 2010, 90(5), 531-532.
15. Scarpa, R.; Lubrano, E.; Cozzi, R.; Ames, P.R.; Oriente, C.B.; Oriente, P. Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? Br. J. Rheumatol., 1997, 36(5), 602-603.
16. Marzano, A.V.; Cugno, M.; Trevisan, V.; Lazzari, R.; Fanoni, D.; Berti, E.; Crosti, C. Inflammatory cells, cytokines and matrix metalloproteinases in amicrobial pustulosis of the folds and other neutrophilic dermatoses. Int. J. Immunopathol. Pharmacol., 2011, 24(2), 451-460.
17. Rohekar, G.; Inman, R.D. Conundrums in nosology: synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and spondylarthritis. Arthritis Rheum., 2006, 55(4), 665-669.
18. Kalke, S.; Perera, S.D.; Patel, N.D.; Gordon, T.E.; Dasgupta, B. The sternoclavicular syndrome: experience from a district general hospital and results of a national postal survey. Rheumatology (Oxford), 2001, 40(2), 170-177.
19. Queiro, R.; Moreno, P.; Sarasqueta, C.; Alperi, M.; Riestra, J.L.; Ballina, J. Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin. Exp. Rheumatol., 2008, 26(1), 125-128.
20. Depasquale, R.; Kumar, N.; Lalam, R.K.; Tins, B.J.; Tyrrell, P.N.; Singh, J.; Cassar-Pullicino, V.N. SAPHO: What radiologists should know. Clin. Radiol., 2012, 67(3), 195-206.
21. Jung, J.; Molinger, M.; Kohn, D.; Schreiber, M.; Pfreundschuh, M.; Assmann, G. Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome. Semin. Arthritis Rheum., 2012, 42(3), 266-270.
22. Hayama, K.; Inadomi, T.; Fujisawa, D.; Terui, T. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur. J. Dermatol., 2010, 20(6), 758-762.
23. Assmann, G.; Kueck, O.; Kirchhoff, T.; Rosenthal, H.; Voswinkel, J.; Pfreundschuh, M.; Zeidler, H.; Wagner, A.D. Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study. Arthritis Res. Ther., 2009, 11(5), R140.
24. Amital, H.; Applbaum, Y.H.; Aamar, S.; Daniel, N.; Rubinow, A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford), 2004, 43(5), 658-661.
25. Colina, M.; La Corte, R.; Trotta, F. Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin. Exp. Rheumatol., 2009, 27(1), 112-115.
26. Delattre, E.; Guillot, X.; Godfrin-Valnet, M.; Prati, C.; Wendling, D. SAPHO syndrome treatment with intravenous pamidronate. Retrospective study of 22 patients. Joint Bone Spine, 2014.
27. Olivieri, I.; Padula, A.; Ciancio, G.; Salvarani, C.; Niccoli, L.; Cantini, F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann. Rheum. Dis., 2002, 61(4), 375-376.
28. Wagner, A.D.; Andresen, J.; Jendro, M.C.; Hulsemann, J.L.; Zeidler, H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum., 2002, 46(7), 1965-1968.
29. Burgemeister, L.T.; Baeten, D.L.; Tas, S.W. Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome. Neth. J. Med., 2012, 70(10), 444-449.
30. Hayem, G.; M'Barek, R.B.; Toussirot, E.; Compaore, C.; Pham, T.; Houvenagel, E.; Martin, A.; Balandraud, N.; Berthelot, J.; Cormier, G.; Dubois, A.; Javier, R.; Lanot, S.; M., W.; Meyer, O.C.; Wendling, D. Abstracts of the American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting. November 6-11, 2010. Atlanta, Georgia, USA. Arthritis Rheum., 2010, 62 (Suppl 10), 1.
31. Laveti, D.; Kumar, M.; Hemalatha, R.; Sistla, R.; Naidu, V.G.; Talla, V.; Verma, V.; Kaur, N.; Nagpal, R. Anti-inflammatory treatments for chronic diseases: a review. Inflamm. Allergy Drug Targets, 2013, 12(5), 349-361.
32. Hurtado-Nedelec, M.; Chollet-Martin, S.; Nicaise-Roland, P.; Grootenboer-Mignot, S.; Ruimy, R.; Meyer, O.; Hayem, G. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford), 2008, 47(8), 1160-1167.
33. Robinson, A.; Van Voorhees, A.S.; Hsu, S.; Korman, N.J.; Lebwohl, M.G.; Bebo, B.F., Jr.; Kalb, R.E. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol., 2012, 67(2), 279-288.
34. Haslund, P.; Lee, R.A.; Jemec, G.B. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm. Venereol., 2009, 89(6), 595-600.
35. Adisen, E.; Gurer, M.A. Therapeutic options for palmoplantar pustulosis. Clin. Exp. Dermatol., 2010, 35(3), 219-222.
36. Delage, M.; Samimi, M.; Atlan, M.; Machet, L.; Lorette, G.; Maruani, A. Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers. Acta Derm. Venereol., 2011, 91(2), 169-171.
37. Moll, C.; Hernandez, M.V.; Canete, J.D.; Gomez-Puerta, J.A.; Soriano, A.; Collado, A.; Sanmarti, R. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin. Arthritis Rheum., 2008, 37(5), 299-306.
38. Massara, A.; Cavazzini, P.L.; Trotta, F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford), 2006, 45(6), 730-733.
39. De Souza, A.; Solomon, G.E.; Strober, B.E. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull. NYU Hosp. Jt. Dis., 2011, 69(2), 185-187.
40. Salles, M.; Olive, A.; Perez-Andres, R.; Holgado, S.; Mateo, L.; Riera, E.; Tena, X. The SAPHO syndrome: a clinical and imaging study. Clin. Rheumatol., 2011, 30(2), 245-249.
41. Fruehauf, J.; Cierny-Modre, B.; Caelen Lel, S.; Schwarz, T.; Weinke, R.; Aberer, E. Response to infliximab in SAPHO syndrome. BMJ Case Rep., 2009, 2009, pii: bcr10.2008.1145.
42. Ben Abdelghani, K.; Dran, D.G.; Gottenberg, J.E.; Morel, J.; Sibilia, J.; Combe, B. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J. Rheumatol., 2010, 37(8), 1699-1704.
43. Zhang, L.L.; Zhao, J.X.; Liu, X.Y. Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study. Rheumatol. Int., 2012, 32(7), 1963-1965.
44. Arias-Santiago, S.; Sanchez-Cano, D.; Callejas-Rubio, J.L.; Fernandez-Pugnaire, M.A.; Ortego-Centeno, N. Adalimumab treatment for SAPHO syndrome. Acta Derm. Venereol., 2010, 90(3), 301-302.
45. Garcovich, S.; Amelia, R.; Magarelli, N.; Valenza, V.; Amerio, P. Long-term treatment of severe SAPHO syndrome with adalimumab: case report and a review of the literature. Am. J. Clin. Dermatol., 2012, 13(1), 55-59.
46. Henriques, C.C.; Sousa, M.; Panarra, A.; Riso, N. The dark side of SAPHO syndrome. BMJ Case Rep., 2011, 2011, pii: bcr1120115197.
47. Brunasso, A.M.; Laimer, M.; Massone, C. Paradoxical reactions to targeted biological treatments: A way to treat and trigger? Acta Derm. Venereol., 2010, 90(2), 183-185.
48. Wendling, D.; Prati, C.; Aubin, F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum. Dis., 2012, 71(6), 1098-1100.
49. Colina, M.; Pizzirani, C.; Khodeir, M.; Falzoni, S.; Bruschi, M.; Trotta, F.; Di Virgilio, F. Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford), 2010, 49(7), 1416-1418.
50. Firinu, D.; Lorrai, M.M.; Barca, M.P.; Peralta, M.M.; Mura, M.N.; Perra, S.; Cabras, S.; Manconi, P.E.; Del Giacco, S.R. Increased peripheral T(H)17 Cells in SAPHO syndrome: a novel target for treatment? Allergy, 2013, 68, 198-199.
51. Chimenti, M.S.; Teoli, M.; Saraceno, R.; Dattola, A.; Ventura, A.; Chiricozzi, A.; Chiaramonte, C.; Perricone, R.; Chimenti, S. Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology, 2013, 227(4), 305-310.
52. Gerdes, S.; Franke, J.; Domm, S.; Mrowietz, U. Ustekinumab in the treatment of palmoplantar pustulosis. Br. J. Dermatol., 2010, 163(5), 1116-1118.
53. Benucci, M.; Saviola, G.; Baiardi, P.; Manfredi, M.; Sarzi-Puttini, P.; Atzeni, F. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int. J. Immunopathol. Pharmacol., 2011, 24(1), 269-274.
54. Garces, S.; Demengeot, J.; Benito-Garcia, E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis., 2013, 72(12), 1947-1955.
55. Meyer, M.W.; Zachariae, C.; Bendtzen, K.; Skov, L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm. Venereol., 2012, 92(4), 362-364.
56. Colina, M.; Trotta, F. Clinical and radiological characteristics of SAPHO Syndrome. Curr. Rheumatol. Rev., 2013, 9(1), 22-27.
57. Marotte, H.; Cimaz, R. Etanercept-TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin. Biol. Ther., 2014, 14(5), 569-572.
58. Colina, M.; Pippucci, T.; Moro, M.A.; Marconi, C.; Magini, P.; Ciancio, G.; Romeo, G.; Trotta, F.; Seri, M. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome: is PTPN22 involved? Clin. Exp. Rheumatol., 2012, 30(3), 451.
59. Lasiglie, D.; Traggiai, E.; Federici, S.; Alessio, M.; Buoncompagni, A.; Accogli, A.; Chiesa, S.; Penco, F.; Martini, A.; Gattorno, M. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One, 2011, 6(5), e20014.
60. Lukens, J.R.; Gross, J.M.; Calabrese, C.; Iwakura, Y.; Lamkanfi, M.; Vogel, P.; Kanneganti, T.D. Critical role for inflammasomeindependent IL-1beta production in osteomyelitis. Proc. Natl. Acad Sci. U S A, 2014, 111(3), 1066-1071.
61. Aksentijevich, I.; Masters, S.L.; Ferguson, P.J.; Dancey, P.; Frenkel, J.; van Royen-Kerkhoff, A.; Laxer, R.; Tedgard, U.; Cowen, E.W.; Pham, T.H.; Booty, M.; Estes, J.D.; Sandler, N.G.; Plass, N.; Stone, D.L.; Turner, M.L.; Hill, S.; Butman, J.A.; Schneider, R.; Babyn, P.; El-Shanti, H.I.; Pope, E.; Barron, K.; Bing, X.; Laurence, A.; Lee, C.C.; Chapelle, D.; Clarke, G.I.; Ohson, K.; Nicholson, M.; Gadina, M.; Yang, B.; Korman, B.D.; Gregersen, P.K.; van Hagen, P.M.; Hak, A.E.; Huizing, M.; Rahman, P.; Douek, D.C.; Remmers, E.F.; Kastner, D.L.; Goldbach-Mansky, R. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med., 2009, 360(23), 2426-2437.
62. Eleftheriou, D.; Gerschman, T.; Sebire, N.; Woo, P.; Pilkington, C.A.; Brogan, P.A. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford), 2010, 49(8), 1505-1512.
63. Moll, M.; Kuemmerle-Deschner, J.B. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clin. Immunol., 2013, 147(3), 242-275.
64. Pham, T.N.; Rahman, P.; Richardson, V.J. Divergent effects of infliximab and anakinra therapies on macrophage phenotype from patients with refractory rheumatoid arthritis. Int. J. Immunopathol. Pharmacol., 2010, 23(2), 491-501.
65. Castrichini, M.; Lazzerini, P.E.; Gamberucci, A.; Capecchi, P.L.; Franceschini, R.; Natale, M.; Hammoud, M.; Moramarco, A.; Zimbone, S.; Gianchecchi, E.; Montilli, C.; Ricci, G.; Selvi, E.; Cantarini, L.; Galeazzi, M.; Laghi-Pasini, F. The purinergic P2x7 receptor is expressed on monocytes in Behcet's disease and is modulated by TNFalpha. Eur. J. Immunol., 2013, [E-pub ahead of print].
66. Scholtysek, C.; Kronke, G.; Schett, G. Inflammation-associated changes in bone homeostasis. Inflamm. Allergy Drug Targets, 2012, 11(3), 188-195.
67. Hofmann, S.R.; Morbach, H.; Schwarz, T.; Rosen-Wolff, A.; Girschick, H.J.; Hedrich, C.M. Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin. Immunol., 2012, 145(1), 69-76.
68. Abu-Amer, Y.; Darwech, I.; Otero, J. Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss. Autoimmunity, 2008, 41(3), 204-211.
69. Sharon, V.R.; Garcia, M.S.; Bagheri, S.; Goodarzi, H.; Yang, C.; Ono, Y.; Maverakis, E. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm. Venereol., 2012, 92(3), 320-321.
70. Hermanns-Le, T.; Berardesca, E.; Pierard, G.E.; Lesuisse, M.; Pierard-Franchimont, C. Challenging regional psoriasis and ustekinumab biotherapy: impact of the patterns of disease. J. Biomed. Biotechnol., 2012, 2012, 413767.
71. Marzano, A.V.; Ishak, R.S.; Saibeni, S.; Crosti, C.; Meroni, P.L.; Cugno, M. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin. Rev. Allergy Immunol., 2013, 45(2), 202-210.